Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | KRAS | P01116 | 3/20 | 0.32 |
| ▸ | FABP3 | P05413 | 1/20 | 0.32 |
| ▸ | FABP2 | P12104 | 1/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15712255 | 0.82 | HTR2A (0.54) | HTR2AHTR2CSLC6A2SLC6A4NTSR1 | |
| SCHEMBL30861517 | 0.82 | HTR2A (0.54) | HTR2AHTR2CSLC6A2SLC6A4NTSR1 | |
| SCHEMBL20876078 | 0.80 | HTR2C (0.49) | HTR2AHTR2CSLC6A2SLC6A4CYP2A6 | |
| SCHEMBL20876045 | 0.80 | HTR2A (0.49) | HTR2AHTR2CSLC6A2SLC6A4CYP2A6 | |
| SCHEMBL22320201 | 0.76 | HTR2A (0.37) | HTR2AHTR2C | |
| SCHEMBL22320205 | 0.76 | CDC7 (0.40) | CYP2A6 | |
| SCHEMBL30861604 | 0.75 | HTR2A (0.46) | HTR2AHTR2CSLC6A2SLC6A4NTSR1 | |
| SCHEMBL22320222 | 0.75 | HTR2A (0.37) | HTR2AHTR2C | |
| SCHEMBL16627457 | 0.74 | HTR2A (0.47) | HTR2AHTR2CSLC6A2SLC6A4NTSR1 | |
| SCHEMBL22798848 | 0.74 | NTSR1 (0.50) | HTR2AHTR2CSLC6A2SLC6A4NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11629138-B2 | Microbiocidal picolinamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-18 | — | — | US | disclosed |
| EP-3692029-B1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| US-20200255400-A1 | Microbiocidal Picolinamide Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255400-A1 | Microbiocidal Picolinamide Derivatives | PRF1, CASP1, FPR1 | HTR2A 1946/4885HTR2C 2046/4885SLC6A2 3920/4885 |
| US-11629138-B2 | Microbiocidal picolinamide derivatives | PRF1, CASP1, FPR1 | HTR2A 1946/4885HTR2C 2046/4885SLC6A2 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.